CYBN
HealthcareCybin Inc.
$8.28
+$0.10 (+1.22%)
Jan 2, 2026
Price History (1Y)
Analysis
Cybin Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $413.12M and approximately 50 employees. As a biotech firm, Cybin's operations are focused on developing innovative treatments and technologies. The company's financial health appears to be challenged, with significant losses reported in the trailing twelve months (TTM). Net income came in at -$86,798,672, while EBITDA was -$98,725,328. The gross margin, operating margin, and profit margin were all 0.0%. Returns on equity and assets were also negative, standing at -53.0% and -32.9%, respectively. Despite this, the company has a substantial cash balance of $83.75M and manageable debt levels of $28.89M. Cybin's valuation metrics indicate a significant discount to its earnings. The forward price-to-earnings ratio is -2.82, suggesting that investors may be expecting future growth or improvements in profitability. However, this metric should be viewed within the context of the company's current financial performance and overall market trends. Dividend payments are not a consideration for Cybin at present, given its zero payout ratio.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Cybin Inc.
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Visit website →Key Statistics
- Market Cap
- $413.12M
- P/E Ratio
- N/A
- 52-Week High
- $10.73
- 52-Week Low
- $4.81
- Avg Volume
- 878.16K
- Beta
- 0.79
Company Info
- Industry
- Biotechnology
- Exchange
- ASE
- Country
- Canada
- Employees
- 50